Business Wire

CA-ANDERSEN-GLOBAL

Del
Andersen Global går ind i New Zealand og tilføjer to samarbejdende virksomheder

Andersen Global etablerer skattemæssige og juridiske kompetencer i New Zealand gennem samarbejdsaftaler med to virksomheder beliggende i Auckland – advokatfirmaet Turner Hopkins og skatte- og rådgivningsfirmaet Bellingham Wallace. Virksomhederne opretholder solide forbindelser i regionen og vil spille en central rolle i at drive forretning og levere integrerede, globale løsninger for at skabe langsigtet værdi for kunderne.

Turner Hopkins blev grundlagt i 1923 og har i næsten 100 år leveret fuldservice-kompetencer inden for ejendomsret, selskabs- og erhvervsret, procesførelse, finans, ansættelsesret, familieret, private kunder, ejendoms- og immigrationsret. Turner Hopkins’ tværfaglige team af fagfolk har stor erfaring med at arbejde på tværs af en række brancher og tage sig af kundernes behov med omfattende, skræddersyede løsninger.

”Vi er stolte over vores kundefokuserede tilgang og vores forpligtelse til at sikre, at vi fastholder den højeste kaliber af advokater og fagfolk, hvilket har gjort det muligt for os at opretholde en konkurrencefordel i Auckland-regionen i næsten et århundrede,” siger ledende partner Michael Robinson. ”Samarbejdet med Andersen Global gør os i stand til fortsat at arbejde problemfrit med kunder og levere kvalitetsløsninger til kunder med stigende globale behov”.

Bellingham Wallace blev etableret i 2012 og grundlagt af to ledende partnere Matt Bellingham og Aaron Wallace, for at arbejde tæt sammen med kunder lige fra små til store privatejede virksomheder. Virksomheden tilbyder en række fuldservice-kompetencer inden for rådgivning, ledelse, skat, strategi, due diligence og værdiansættelse for at drive vækst og styre risici for kundernes virksomheder.

”Vores virksomhed har oplevet enestående vækst i løbet af de seneste par år, alt imens vi fortsætter med at prioritere alle vores kunders behov og udvide vores eksisterende kapaciteter på markedet,” siger medgrundlægger og ledende medpartner Matt Bellingham. ”Samarbejdet med Andersen Global viser vores forpligtelse til ekspertise og styrker vores kundefokuserede tilgang, da de yderligere globale ressourcer vil styrke vores evne til at imødekomme kundernes skiftende behov,” tilføjer Aaron Wallace.

Andersen Globals bestyrelsesformand og CEO Mark Vorsatz siger: ”Turner Hopkins og Bellingham Wallace vil være store aktiver i vores bestræbelse på at imødekomme vores voksende behov i regionen. Disse virksomheder deler vores organisations engagement i ledelse og udviser de højeste professionelle standarder, og vi forudser et synergistisk samarbejde mellem vores fagfolk. Det er vigtigt for os at samarbejde med disse virksomheder, mens vi fortsat giver klassens bedste løsninger til vores kunder over hele kloden og styrker vores tilstedeværelse i Asien og Stillehavsområdet.”

Andersen Global er en international sammenslutning af juridisk adskilte, uafhængige medlemsvirksomheder, bestående af skatte- og juraeksperter i hele verden. Andersen Global blev stiftet af den amerikanske medlemsvirksomhed Andersen Tax LLC i 2013, og Andersen Global har nu over 11.000 fagfolk på verdensplan og er repræsenteret på mere end 360 lokaliteter via sine medlemsvirksomheder og samarbejdende virksomheder.

Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release

Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc

Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release

SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f

Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press release

Through the Extreme Exchange (IX) acquisition, Megaport gains seven Internet Exchanges and access to 40+ data centres across India’s fastest-growing digital hubs. Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly thr

IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 22:10:00 CET | Press release

Extension solidifies QuantumBasel as IonQ’s Innovation Center in Europe; adds IonQ Tempo and next-generation system to advance quantum commercialization IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerston

Suzano Starts Up New Production Line, Boosting Its Fluff Pulp Capacity by 400%17.12.2025 21:50:00 CET | Press release

A R$490 million investment expands the supply of raw material used in the production of absorbent items Suzano, the world’s largest pulp producer, has commenced operations this week at its new fluff pulp production line located in its Limeira unit in Brazil’s São Paulo state. This R$490 million investment increases Suzano’s total fluff pulp production capacity by more than 400%, from 100,000 to 440,000 tonnes per year. The project involved converting the existing pulp line at the Limeira unit into a flexible machine, capable of producing both Eucafluff® and market pulp. Eucafluff® is used in the production of absorbent and personal hygiene products, such as baby and adult diapers, sanitary pads and pet pads. Then market pulp is supplied for making products including toilet paper, printing and writing papers, and paper packaging. Launched in 2015, Eucafluff® is the world’s first fluff pulp made from eucalyptus, delivering unique advantages like enhanced softness and flexibility, which t

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye